Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Gestational Diabetes Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The gestational diabetes market size has demonstrated significant expansion over recent years. Its valuation is projected to increase from $9.11 billion in 2025 to $9.93 billion in 2026, advancing at a compound annual growth rate (CAGR) of 8.9%. Historically, this growth has been driven by increasing obesity rates, higher maternal age pregnancies, early diabetes screening programs, growth in prenatal care services, and heightened awareness of pregnancy complications.
The gestational diabetes market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $13.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This anticipated growth during the forecast timeframe is primarily driven by factors such as an increase in the prevalence of gestational diabetes, the broadening scope of digital health monitoring, advancements in prenatal diagnostics, a heightened emphasis on preventive maternal care, and supportive healthcare policies. Key trends expected to shape this period encompass the increasing uptake of blood glucose monitoring, a rise in the application of insulin therapy during pregnancy, an evolving focus on lifestyle-centric disease management, the expansion of prenatal screening initiatives, and enhanced awareness regarding maternal health.
Get A Free Sample Report With In-Depth Market Insights:
Gestational Diabetes Market Growth Momentum: What Factors Are Shaping Demand?
The expanding obese population is anticipated to fuel the growth of the gestational diabetes market in the future. This population consists of individuals with a body mass index (BMI) of 30 or above, signifying excess body fat that could present considerable health dangers. The rise in the obese population is attributed to a combination of inactive lifestyles, increased intake of high-calorie, processed foods, genetic predispositions, and restricted availability of healthy dietary and exercise choices. Managing gestational diabetes is vital for the obese population due to their elevated risk of insulin resistance and substantial weight gain during pregnancy, which, if not controlled, can result in health issues for both the mother and the infant. For example, in May 2025, data from the Office for Health Improvement and Disparities, a UK-based government organization, showed that between 2023 and 2024, approximately 64.5% of adults aged 18 and above in England were classified as overweight or living with obesity, an increase from 64.0% recorded in 2022 to 2023. Consequently, the growing obese population is a significant factor propelling the gestational diabetes market.
Gestational Diabetes Market Segment Landscape: Which Areas Lead Development?
The gestational diabetes market covered in this report is segmented –
1) By Type: Type A1, Type A2, Other Types
2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological Treatment
3) By Administration: Oral, Intravenous, Other Administrations
4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers
Subsegments:
1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes
2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes
3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications
Gestational Diabetes Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the gestational diabetes market are prioritizing the creation of technologically advanced products, such as diagnostic kits specifically for gestational diabetes, to facilitate quick, accurate, and convenient methods for early detection. A diagnostic kit for gestational diabetes functions as a medical instrument employed to assess blood glucose levels and identify atypical glucose tolerance in expectant mothers, thereby aiding in the condition’s prompt identification and management. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology firm, introduced the XpressGT RUO kit, a diagnostic solution designed for the diagnosis of gestational diabetes, endometriosis, insulin resistance, and liver disease. This kit accurately quantifies 2-hydroxybutyrate (2-HB) levels found in venous blood, a compound naturally produced by the liver during its normal activities. Elevated 2-HB concentrations are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The XpressGT RUO kit works with any available clinical analyzer and provides results in just 8 minutes, offering a rapid and efficient diagnostic solution.
Gestational Diabetes Market Industry Leaders And Competitive Landscape
Major companies operating in the gestational diabetes market are Sanofi S.A., Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton Dickinson and Company, Dexcom Inc, Biocon Limited, Ascensia Diabetes Care Holdings AG, Roche Diabetes Care, Medtronic plc, Insulet Corporation, Tandem Diabetes Care Inc, Ypsomed Holding AG, Beta Bionics Inc, Bigfoot Biomedical Inc, Glooko Inc, Philips Healthcare, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Pfizer Inc, Novartis AG, Adocia SA, Daiichi Sankyo Company Ltd
View The Full Gestational Diabetes Market Report:
Gestational Diabetes Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the gestational diabetes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
